<DOC>
	<DOCNO>NCT00509964</DOCNO>
	<brief_summary>Patients recurrent metastatic gastric cancer benefit palliative chemotherapy . However , half patient metastatic gastric cancer receive chemotherapy fail achieve response even responder , duration response short month . Patients metastatic gastric cancer fail respond relapse first line chemotherapy grim prognosis standard salvage treatment available . We design phase II trial determine efficacy safety irinotecan monotherapy combination ( ILF ) second-line therapy advance gastric cancer .</brief_summary>
	<brief_title>Second-Line Irinotecan vs. ILF AGC</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>histologically confirm gastric cancer inoperable , recurrent , metastatic performance status 0 2 fail one prior chemotherapy advance disease inform consent active infection severe comorbidities previously treat irinotecan similar drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>